In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment ...
Jul 10, 2025
0
16
For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone, according ...
Jun 5, 2025
0
15
Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy without increasing the risk of severe lung inflammation (pneumonitis). This is the key finding of a ...
May 13, 2025
0
23
A new trial of patients with advanced rectal cancer has found that the addition of immunotherapy treatment alongside extended radiotherapy led to better rates of remission.
May 9, 2025
0
26
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder ...
Feb 17, 2025
0
10
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.
Nov 22, 2024
0
27
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor ...
Oct 11, 2024
0
64
Despite recent advances in the treatment of breast cancer, it remains the second leading cause of cancer death in the U.S. and worldwide. There is a continued need to improve treatment strategies and therapies that not only ...
Oct 1, 2024
0
39
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when ...
Sep 30, 2024
0
31
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer overall and progression-free survival, according to a study published online Sept. 13 in the New England ...
Sep 19, 2024
0
21
